RxDoctor Payments Data
★ My doctorsLook up a doctor →

David Daniels, MD

Interventional Cardiology · Burlingame, CANPI 1629121975

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.5%), travel and lodging and royalties or licence payments — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 60.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $83,470 and has fallen 69.8% since, to $25,182 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$318,681in general payments, 2019–2025

Across 532 payments — averaging $599.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$192K
  • Teleflex LLC$59K
  • Jenavalve Technology, Inc.$22K
  • Vascular Solutions, Inc.$15K
  • Abbott$15K
  • Medtronic$14K
  • plus $2K from 14 others
$1,874,178in research payments, 2019–2025

Across 179 payments — averaging $10,470 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.8M
  • Boston Scientific$67K
  • Medtronic$950

What the payments were for

  • Royalty or licence$33,21310%
  • Consulting fees$173,58054%
  • Speaking & faculty fees$24,1258%
  • Travel & lodging$57,67618%
  • Food & beverage$14,8885%
  • Education$15,2005%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences369$191,728
Teleflex LLC46$59,286
Jenavalve Technology, Inc.8$21,731
Vascular Solutions, Inc.6$15,153
Abbott17$14,758
Medtronic(2 entities)42$13,853
Boston Scientific11$720
Abiomed3$276
Shockwave Medical, Inc10$238
Philips North America LLC5$195
Acist Medical Systems, Inc.4$185
Biotronik Inc.1$158
Cardiovascular Systems Inc.1$100
Seigla Medical, Inc.1$86
Terumo Medical Corporation2$53
Teleflex Medical Canada Inc.1$48
Angiodynamics, Inc.1$45
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$26
Merit Medical Systems Inc1$23
Arrow International, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$318,681 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$323,808
Medicare patients
272
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$12,498
Nitroglycerin PatchNitroglycerin11$269
Memantine Hcl11$220
Levothyroxine Sodium12$164
ClopidogrelClopidogrel Bisulfate15$77

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Burlingame

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →